Array’s Receipt of Non‑Binding Proposal from TDS
May 08, 2026
On May 8, 2026, Array Digital Infrastructure, Inc. (“Array”) confirmed that its board of directors has received a non‑binding proposal from Telephone and Data Systems, Inc. (“TDS”) to acquire all of the outstanding common shares of Array not currently owned by TDS. Currently, TDS owns approximately 81.9% of the outstanding capital stock of and 95.9% of the voting interests in Array. The proposal is conditioned on, among other things, the recommendation of a special committee of disinterested and independent directors of Array and the approval by a majority of the votes cast by disinterested stockholders. Cravath is representing the special committee in connection with the proposal.
The Cravath team is led by partners G.J. Ligelis Jr. and Edward O. Minturn and includes associates Penina Su and Reva Bardhi.
Related Practices & Industries
People
- Photo
-
-
J.D., 2009, Harvard Law Schoolcum laude
-
A.B., 2006, Princeton UniversityPhi Beta Kappa, magna cum laude
- New York
Education
Admitted In
- Photo
-
-
J.D., 2016, New York University School of Lawcum laude
-
B.A., 2013, Duke Universitywith Distinction
- New York
Education
Admitted In
Related News & Insights
Deals & Cases
May 01, 2026
Integris’ Planned Acquisition of First Focus
On April 27, 2026, Integris, a national leader in managed AI and IT services backed by OMERS Private Equity, announced its intent, subject to regulatory approval, to acquire First Focus, the largest managed service provider serving small and midsize businesses in Australia, New Zealand and the Philippines. Cravath is representing Integris as U.S. counsel in connection with the transaction.
Deals & Cases
April 27, 2026
Thermo Fisher’s $1.075 Billion Sale of its Microbiology Business to Astorg
On April 27, 2026, Thermo Fisher Scientific Inc. (“Thermo Fisher”), the world leader in serving science, announced that it has signed a definitive agreement to sell its microbiology business, which provides antimicrobial susceptibility testing and culture media solutions for clinical, pharmaceutical and food safety testing, to Astorg, a leading pan‑European private equity firm, for consideration of approximately $1.075 billion, consisting of cash and a $50 million seller note. Cravath is representing Thermo Fisher in connection with the transaction.
Deals & Cases
March 31, 2026
Biogen’s $5.6 Billion Acquisition of Apellis
On March 31, 2026, Biogen Inc. and Apellis Pharmaceuticals, Inc. announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire all outstanding shares of Apellis for $41.00 per share in cash at closing, or approximately $5.6 billion. Apellis stockholders will also receive a nontransferable CVR for each Apellis share held, entitling the holder to receive two payments of $2 per share each, contingent on certain annual global net sales thresholds being met for SYFOVRE®. Cravath is representing Biogen in connection with the transaction.
Deals & Cases
March 11, 2026
Elsevier’s Acquisition of Mytonomy
On March 10, 2026, Elsevier, a global leader in advanced information and decision support and part of RELX, announced it has entered into a definitive agreement to acquire Mytonomy, a leader in video-based patient engagement solutions that will complement Elsevier’s Clinical Solutions portfolio. Cravath is representing RELX in connection with the transaction.
